Proprietary Enzyme Therapeutics
Undisclosed
DiscoveryActive
Key Facts
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a mission-driven company focused on advancing molecular research, diagnostics, and therapeutics through specialized enzymatic solutions derived from Arctic organisms. Its key achievement is the invention of salt-active nucleases and COD UNG, establishing it as a critical supplier to the global IVD and biomanufacturing industries. The company's strategy is to deepen its penetration in the high-growth gene therapy and vaccine manufacturing markets while expanding its therapeutic pipeline. With over 30 years of expertise, ArcticZymes combines a stable commercial enzyme business with a forward-looking therapeutic development arm.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| Amgen Collaboration Program | Xeris Biopharma | Pre-clinical |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |